Navigation Links
Common drug for stopping preterm labor may be harmful for babies
Date:11/1/2007

A drug commonly used to halt premature labor may be associated with brain damage and intestinal issues in premature babies, according to a new analysis of studies on the issue published today in American Journal of Obstetrics and Gynecology.

When a woman goes into labor early, obstetricians are faced with the possibility of delivering a baby who is not ready to breathe air on its own. Often the mother will be given both a tocolytic agent, or drug used to stop labor, and a steroid to help the babys lungs mature faster. After the baby has had a couple days to allow the steroid to work, the tocolytic agent will be stopped and the mother may give birth shortly after.

As pediatricians and neonatalogists, its important for us to know whether the benefit of these drugs outweighs the potential for complications for these medically fragile children, said Sanjiv Amin, M.D., assistant professor of Pediatrics at the University of Rochester Medical Center and author of an article on the subject. In the case of the tocolytic agent indomethacin, we know it impacts blood flow but there have been no large randomized studies to evaluate the effects on the baby.

Dozens of studies have been done, but none have had a large sample size or a definitive outcome on the effects of indomethacin. The new analysis of a collection of studies, or a metaanalysis, by University of Rochester Medical Center researchers pulls together enough data to conclude that there is an association between use of indomethacin and babies experiencing periventricular leukomalacia (white matter injury by decreasing blood flow in the brain, which may lead to cerebral palsy).

The analysis also showed an association between indomethacin and necrotizing entercolitis (a condition in which intestinal tissue dies, which can sometimes be successfully treated with antibiotics but can require surgery and even cause death), especially for those babies who were exposed to the drug within days of birth. However, use of antenatal indomethacin is not associated with intraventricular hemorrhage (bleeding in the brain), patent ductus arteriosus (a congenital heart defect), respiratory distress syndrome (a life-threatening lung disorder) or death.

Obstetricians often use indomethacin only when women go into labor extremely early. But many obstetricians believe it is more effective and has fewer side effects for the mother than other commonly used tocolytic agents, and so they may use it for woman whose babies are farther along.

Christopher Glantz, M.D., M.P.H., professor of Obstetrics and Gynecology at the University of Rochester Medical Center and a co-author of the paper, said he hopes the analysis will encourage obstetricians to use the drug only when women are in labor very early when their babies are at most risk of the problems related to prematurity.

Its important for us to realize that these drugs are not benign, Glantz said. None of the drugs we have to stop labor work all that well, and were stuck between a rock a premature baby who could benefit from more time in the womb and a hard place a baby who may develop problems because of drugs such as indomethacin that may provide extra time in the womb.

We need to use the drug only on those who need it most.


'/>"/>

Contact: Heather Hare
heather_hare@urmc.rochester.edu
585-273-2840
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Developmental, neurologic problems common in extremely preterm infants
2. Iron supplementation for a common side effect
3. Genetic Breakthrough in Common Eye Problem
4. Common Cold Found to Fight Cancer Cells
5. Side Effects Of Some Common Drugs
6. E. coli strains resistant to a common antibiotic
7. Gastrointestinal ills more common in diabetics
8. Toxic effects common with AIDS treatments
9. Common contraception
10. Drooping eyelids more common in men
11. Unnatural death common in mentally ill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Olathe, KS (PRWEB) , ... April 28, 2017 ... ... system have typically been previously exposed to more adverse experiences than children in ... have experienced trauma such as abuse, neglect or other family challenges. While no ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early ... substantially improve drug safety and minimize the cost of development. In this webinar, ... inhibition using cell lines and for cardiac toxicity using induced pluripotent stem cells ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... the Creator responds to and which He does not. Yisrayl says with so many ... is the true name, but he says with a little Scripture, backed with a lot ...
(Date:4/28/2017)... ... 2017 , ... Intellitec Solutions announced the publication of a ... Dynamics GP solution that integrates to their PointClickCare EHR software package. With the ... Brooke Grove now has the capability to achieve its goal for a comprehensive ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that ... his presence to an educational purpose as the host of the “Informed” series. The ... In a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and Markets ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ... offering. ... drug delivery technologies will rise from USD 20 Billion in 2015 ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology: